CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Stoke Therapeutics Q3 net loss widens 92% to $73.64 million

By Public Technologies
  • Stoke Therapeutics’ third-quarter 2026 net loss widened 92% year over year to $73.64 million.
  • Revenue rose 6% year over year to $11.26 million for the quarter.
  • Cash, cash equivalents and marketable securities totaled $358.8 million at September 30, 2026, expected to fund operations into early 2028.
  • Zorevunersen’s Phase 3 EMPEROR data readout is anticipated in Q3 2027, with a U.S. NDA submission planned for H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610291601BIZWIRE_USPR_____20261029_BW090140) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk